Suitability of digoxin as a p-glycoprotein probe: Implications of other transporters on sensitivity and specificity

Journal of Clinical Pharmacology

Volumn 54, Issue 1, 2014, Pages 3-13

  Nader, Ahmed M ^a   Foster, David R ^b,c  

^a Qatar University ^*  (Qatar)

^b PURDUE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Digoxin; Drug drug interaction; OATP; P glycoprotein; Transporter

Indexed keywords

CYCLOSPORIN; DIGOXIN; FEXOFENADINE; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; RITONAVIR; TALINOLOL; VERAPAMIL; VINBLASTINE; VINCRISTINE;

CLINICAL TRIAL (TOPIC); DRUG DISPOSITION; DRUG INTERACTION; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG UPTAKE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; SENSITIVITY AND SPECIFICITY;

DIGOXIN; DRUG-DRUG INTERACTION; OATP; P-GLYCOPROTEIN; TRANSPORTER;

ANIMALS; CARRIER PROTEINS; DIGOXIN; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HUMANS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS;

EID: 84893258687     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.200     Document Type: Review

References (52)

1. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics:clinical implications. Clin Pharmacokinet. 2003;42(1):59-98
2. Endres CJ, Hsiao P, Chung FS, Unadkat JD. The role of transporters in drug interactions. Eur J Pharm Sci. 2006;27(5):501-517
3. Benet LZ. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm. 2009;6(6):1631-1643
4. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78 (3):260-277
5. Glasser H. Importance of P-glycoprotein for drug-drug interactions. In: FrpmmMF and Kim RB (eds.), Drug Transporters, Handbook of Experimental Pharmacology. Springer-Verlag, Berlin. 2011. 285- 297
6. Center for Drug Evaluation and Research US FDA. Draft Guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling. Feb 2012 [cited Feb 12,2012]; Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM292362.pdf [Online
7. Chowbay B, Li H, David M, Cheung YB, Lee EJ. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1gene expression. Br J Clin Pharmacol. 2005;60(2):159-171
8. Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002;72(2):209-219
9. Dickens D, Owen A, Alfirevic A, Pirmohamed M. ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein. Pharmacogenet Genomics. 2013;23(6):314-323
10. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet. 2004;43(9):553-576
11. Ma JD, et al. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet. 2010;49(4):223- 237
12. Shi JG, Zhang Y, Yeleswaram S. The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate. Nat Rev Drug Discov. 2011;10(1):75
13. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-420
14. Beveridge T, Nüesch E, Ohnhaus EE. Absolute bioavailability of digoxin tablets. Arzneimittelforschung. 1978;28(4):701-703
15. Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, Koch-Weser J. iPharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm. 1975;3(3):181-192
16. Tanigawara Y, et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992;263(2):840-845
17. Cavet ME, West M, Simmons NL. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 1996;118(6):1389-1396
18. Mayer U, et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol. 1996;119 (5):1038-1044
19. Hoffmeyer S, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97(7):3473-3478
20. Kawahara M, Sakata A, Miyashita T, Tamai I, Tsuji A. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J Pharm Sci. 1999;88(12):1281-1287
21. Center for Drug Evaluation and Research US FDA. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Sep 2006 [cited 2012 Feb 2012]; Available from URL: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ ucm093664.htm#PgpTransport
22. Taub ME, Podila L, Ely D, Almeida I. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos. 2005;33(11):1679-1687
23. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation. 1999;99(4):552-557
24. Mayer U, Wagenaar E, Dorobek B, Beijnen J, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest. 1997;100(10):2430-2436
25. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96(4):1698-1705
26. Westphal K, et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther. 2000;68(1):6-12
27. Greiner B, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. [Erratum appears in J Clin Invest 2002 Aug;110(4):571]. J Clin Invest. 1999;104(2):147- 153
28. Igel S, et al. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clin Pharmacokinet. 2007;46(9):777- 785
29. Hedman A, et al. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther. 1991;49(3):256-262
30. Ding R, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004;76(1):73-84
31. Drescher S, et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 2003;73(3):223- 231
32. Noé B, Hagenbuch B, Stieger B, Meier PJ. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA. 1997;94(19):10346-10350
33. Kodawara T, et al. Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm Res. 2002;19(6):738-743
34. Lau YY, Wu CY, Okochi H, Benet LZ. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzymetransporter interplay. J Pharmacol Exp Ther. 2004;308(3):1040-1045
35. Weiss M, Hung DY, Poenicke K, Roberts MS. Kinetic analysis of saturable hepatic uptake of digoxin and its inhibition by rifampicin. Eur J Pharm Sci. 2008;34(4-5):345-350
36. Weiss M, Li P, Roberts MS. An improved nonlinear model describing the hepatic pharmacokinetics of digoxin: evidence for two functionally different uptake systems and saturable binding. Pharm Res. 2010;27(9):1999-2007
37. Yao H-M, Chiou WL. The complexity of intestinal absorption and exsorption of digoxin in rats. Int J Pharm. 2006;322(1-2):79-86
38. Acharya P, et al. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells. Drug Metab Dispos 2008;36(2):452-460
39. Kullak-Ublick GA, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001;120(2):525-533
40. Taub ME, et al. Digoxin is not a substrate for organic aniontransporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependenttransporter expressed in HEK293 cells. Drug Metab Dispos. 2011;39 (11):2093-2102
41. Kimoto E, Chupka J, Xiao Y, Bi Y-a, Duignan DB. Characterization of digoxin uptake in sandwich-cultured human hepatocytes. Drug Metab Dispos. 2011;39:47-53
42. Olinga P, et al. Characterization of the uptake of rocuronium and digoxin in human hepatocytes: carrier specificity and comparison with in vivo data. J Pharmacol Exp Ther. 1998;285(2):506-510
43. Mikkaichi T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA. 2004;101(10):3569-3574
44. Ishiguro N, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin 2 receptor antagonist, in humans. Drug Metab Dispos. 2006;34(7):1109-1115
45. Degorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacyandtoxicity.AnnuRevPharmacolToxicol.2012;52:249-273
46. Kobayashi Y, Kawakami K, Ohbayashi M, Kohyama N, Yamamoto T. Ribosomal protein L3 mediated the transport of digoxin in Xenopus laevis oocyte. J Toxicol Sci. 2010;35(6):827-834
47. Parker RB, Yates CR, Soberman JE, Laizure SC. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy. 2003;23(8):979- 987
48. Lowes S, Cavet ME, Simmons NL. Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur J Pharmacol. 2003;458(1- 2):49-56
49. De Bruyn T, et al. Determination of OATP-, NTCP- and OCTmediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci. 2011;43(4):297-307
50. Funakoshi S, Murakami T, Yumoto R, Kiribayashi Y, Takano M. Role of organic anion transporting polypeptide 2 in pharmacokinetics of digoxin and beta-methyldigoxin in rats. J Pharm Sci. 2005;94(6):1196-1203
51. Tsujimoto M, Dan Y, Hirata S, Ohtani H, Sawada Y. Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxinin terminal renal failure. Drug Metab. 2008;23(6):406-411
52. Oswald S, Terhaag B, Siegmund W. Handbook of Experimental Pharmacology, Drug Transporters, Vol. 201. New York: Springer;2011